FDA Grants Jaguar Health Family Company Napo Pharma's Request For Waiver Of Fee Associated With PDUFA For Mytesi For 2027 Fiscal Year
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing
Jaguar Health got a fee break from the FDA for one year. This means they can save money while working on new medicines for rare diseases.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.